Dupixent Sales Surge Lifts Sanofi’s Guidance, Markets Still 'Underpenetrated'
Dupixent Markets Largely Untapped
The French major’s anti-inflammatory blockbuster continues to deliver with more than 40% sales growth this quarter, with overall Q2 success prompting an increase of EPS guidance to 15%.
You may also be interested in...
The continent's pharmaceutical sector enjoyed another robust quarter with increased productivity, and price increases, softening the blow of rising energy costs and other challenges across the supply chain.
The costimulatory bispecific antibody REGN5678, meant to turn “cold” prostate cancer tumors “hot” and vulnerable to PD-1 inhibitors, showed early signs of efficacy combined with Libtayo.
The firm’s BTK inhibitor tolebrutinib has been put on clinical hold by the US FDA following liver injuries, but advanced trials should continue as normal since most patients have passed the 60-day mark.